Huang Liusheng, Sok Vong, Aslam-Mir Usman, Marzan Florence, Whalen Meghan, Rosenthal Philip J, Aweeka Francesca
Drug Research Unit, Department of Clinical Pharmacy, University of California at San Francisco, San Francisco, CA, 94110, USA.
Department of Medicine, University of California at San Francisco, San Francisco, CA, 94110, USA.
J Chromatogr Open. 2022 Nov;2. doi: 10.1016/j.jcoa.2022.100042. Epub 2022 Mar 14.
Piperaquine (PQ) is an antimalarial drug that is highly protein-bound. Variation in plasma protein contents may affect the pharmacokinetic (PK) exposure of unbound drug, leading to alteration of clinical outcomes. All published methods for determination of PQ in human plasma measure the total PQ including both bound and unbound PQ to plasma proteins. There is no published method for unbound PQ determination. Here we report an ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method for determination of PQ in human plasma filtrate prepared by filtering human plasma through Millipore Microcon® centrifugal filters (10k NMWL). The filter cup had to be treated with 5% benzalkonium chloride to reduce non-specific binding to the filter devices before filtration of plasma samples. Multiple reactions monitoring (MRM) of the ion pairs 535/288 for PQ and 541/294 for the internal standard (IS) was selected for quantification. When electrospray ionization (ESI) was used, paradoxical matrix effect was observed despite the structure similarity of the deuterated IS: Ion suppression for PQ versus ion enhancement for the PQ-d, even though they were closely eluted: 0.62 min versus 0.61 min. Separation was achieved on Evo C column (50 × 2.1 mm, 1.7 m, Phenomenex Inc.) eluted with 10 mM NHOH and MeCN. When atmospheric pressure chemical ionization in positive mode (APCI) was used for ion source, matrix effect diminished. Separation was achieved on a PFP column (30 × 2.1 mm, 1.7 m, Waters, Corp.) eluted with aqueous 20 mM ammonium formate 0.14% trifluoroacetic acid (A) and methanol-acetonitrile (4:1, v/v) containing 0.1% trifluoroacetic acid (B) at 0.8 mL/min flow rate in a gradient mode: 30-30-80-80-30-30%B (0-0.1-1.0-1.40-1.41-1.50 min). The retention time was 0.67 min for both PQ and the IS. The method was validated with a linear calibration range from 20 to 5,000 pg/mL and applied to clinical samples.
哌喹(PQ)是一种与蛋白质高度结合的抗疟药物。血浆蛋白含量的变化可能会影响游离药物的药代动力学(PK)暴露,从而导致临床结果的改变。所有已发表的测定人血浆中PQ的方法均测定包括与血浆蛋白结合和游离的PQ在内的总PQ。目前尚无已发表的测定游离PQ的方法。在此,我们报告一种超高效液相色谱串联质谱(UHPLC-MS/MS)方法,用于测定通过使用密理博Microcon®离心过滤器(10k NMWL)过滤人血浆制备的人血浆滤液中的PQ。在过滤血浆样品之前,滤杯必须用5%苯扎氯铵处理,以减少与过滤装置的非特异性结合。选择PQ的离子对535/288和内标(IS)的离子对541/294进行多反应监测(MRM)定量。当使用电喷雾电离(ESI)时,尽管氘代内标结构相似,但仍观察到反常的基质效应:PQ出现离子抑制,而PQ-d出现离子增强,尽管它们的洗脱时间相近:分别为0.62分钟和0.61分钟。在Evo C柱(50×2.1 mm,1.7μm,菲罗门公司)上进行分离,以10 mM NHOH和乙腈洗脱。当使用正模式大气压化学电离(APCI)作为离子源时,基质效应减弱。在PFP柱(30×2.1 mm,1.7μm,沃特世公司)上进行分离,以含0.14%三氟乙酸的20 mM甲酸铵水溶液(A)和含0.1%三氟乙酸的甲醇-乙腈(4:1,v/v)(B)为流动相,以0.8 mL/min的流速进行梯度洗脱:30-30-80-80-30-30%B(0-0.1-1.0-1.40-1.41-1.50分钟)。PQ和内标的保留时间均为0.67分钟。该方法在20至5000 pg/mL的线性校准范围内进行了验证,并应用于临床样品。